USPTO serial 97912689
ABSTRA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- TORPEY, KATHERINE ANN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ABSTRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
New York, NY
New York, NY
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew D. Bochner
Andrew D. Bochner Bochner PLLC1040 Avenue of the Americas15th FloorNew York, NY 10018Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable and recorded databases in the field of medical data; downloadable and recorded databases in the field of medical research and development; downloadable and recorded software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable and recorded software for diagnosing medical conditions, prescribing medical treatment and prescriptions, designing clinical trials and forecasting clinical trial results, for searching for clinical trial patients, for analyzing medical images, for analyzing data, for developing pharmaceutical products and chemical compounds, for providing online databases, for processing, accessing, and inputting medical information in the field of medical research and development, and for use in fostering communication and collaboration between healthcare researchers, data scientists, and clinicians in the field of medical research and development; downloadable computer and mobile application software for diagnosing medical conditions, prescribing medical treatment and prescriptions, designing clinical trials and forecasting clinical trial results, for searching for clinical trial patients, for analyzing medical images, for analyzing data, for developing pharmaceutical products and chemical compounds, for providing online databases, for processing, accessing, and inputting medical information in the field of medical research and development, and for use in fostering communication and collaboration between healthcare researchers, data scientists, and clinicians in the field of medical research and development; downloadable and recorded artificial intelligence computer and mobile application software for diagnosing medical conditions, prescribing medical treatment and prescriptions, designing clinical trials and forecasting clinical trial results, for searching for clinical trial patients, for analyzing medical images, for analyzing data, for developing pharmaceutical products and chemical compounds, for providing online databases, for processing, accessing, and inputting medical information in the field of medical research and development, and for use in fostering communication and collaboration between healthcare researchers, data scientists, and clinicians in the field of medical research and development; downloadable and recorded software as a Medical Device (SaMD) for analyzing genome information; downloadable and recorded artificial computer and mobile application software for healthcare, namely for machine learning in the field of healthcare, for diagnosing medical conditions, prescribing medical treatment and prescriptions, designing clinical trials and forecasting clinical trial results, for searching for clinical trial patients, for analyzing medical images, for analyzing data, for developing pharmaceutical products and chemical compounds, for providing online databases, for processing, accessing, and inputting medical information in the field of medical research and development, and for use in fostering communication and collaboration between healthcare researchers, data scientists, and clinicians in the field of medical research and development; downloadable and recorded computer software for database management; Software as a Medical Device (SaMD), downloadable, for diagnosing cancer; downloadable and recorded computer software development tools; Computer software platforms, downloadable, for diagnosing medical conditions, prescribing medical treatment and prescriptions, designing clinical trials and forecasting clinical trial results, for searching for clinical trial patients, for analyzing medical images, for analyzing data, for developing pharmaceutical products and chemical compounds, for providing online databases, for processing, accessing, and inputting medical information in the field of medical research and development, for providing online databases and for use in fostering communication and collaboration between healthcare researchers, data scientists, and clinicians in the field of medical research and development; Recorded computer programs using artificial intelligence (AI) for connecting healthcare researchers and data scientists in the field of medical research and development; Downloadable electronic publications in the nature of journals, articles, case reports, technical notes, editorials, white papers, pamphlets, and blog posts in medical field; Interfaces for computers; Network servers, namely, cloud servers | ACTIVE | — |
| 038 | Telecommunication services, namely, transmission of voice, data, messages, videos, and documents via the Internet and telecommunications networks; digital network telecommunications services; telecommunications gateway services; Computer intercommunication, namely transmission of information via computers connected to the same network and providing telecommunications connections to a global computer network; Communications by computer terminals; Computer aided transmission of messages, information and images; Transmission of data and information by computer and electronic communication networks; Communication services, namely, electronic transmission of voice, data, messages, videos, and documents between data banks; Electronic data interchange services; Providing multiple-user access to a global computer information network; Providing multiple use access to global computer information networks for the transfer and dissemination of a wide range of information; Transmission of electronic mail; Provision of telecommunications access to databases and the internet | ACTIVE | — |
| 042 | Software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; Scientific and medical research; Technological research in the field of artificial intelligence and machine learning; Scientific and technological services, namely, scientific research in the field of design of clinical trials, data analysis, and projection of clinical trial results; Medical research; Scientific research for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OWKIN, INC.
- Other trademarks owned by OWKIN, INC.
- Other trademarks in Class 009
- Other trademarks in Class 038
- Other trademarks in Class 042
- Similar marks named ABSTRA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 10, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 10, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 8, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 10, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 10, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 10, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 30, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 4, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 4, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 4, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 4, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 29, 2024 | ALIE | ASSIGNED TO LIE | — |
| Jul 26, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 26, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 26, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 26, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 26, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 27, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 31, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 31, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 31, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 27, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2023 | NWAP | NEW APPLICATION ENTERED | — |